publication date: Oct. 16, 2020

In Brief

OSUCCC – James receives $7 million Program Project NCI grant renewal

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the Ohio State College of Pharmacy have been awarded a five-year, $7 million competitive Program Project grant renewal from NCI.

This multidisciplinary project grant is the only PPG funded by NCI that is led by a pharmacy investigator, and will allow teams at Ohio State, the University of Illinois – Chicago and University of North Carolina – Greensboro to continue investigating potential anticancer drug leads based on compounds from tropical plants, coastal lichens, cultured cyanobacteria and filamentous fungi.

The grant renewal extends through 2025 and is led by principal investigator A. Douglas Kinghorn, professor and Jack L. Beal Chair of the Division of Medicinal Chemistry and Pharmacognosy at the College of Pharmacy. He is a member of the OSUCCC – James Molecular Carcinogenesis and Chemoprevention Program.

“We are so appreciative of this renewed funding. It will enable us to continue our momentum of discovery in the lab, including further investigation of natural products identified as having potential for anticancer activity,” Kinghorn said in a statement. The grant was initially funded in 2007.

The grant, which initially received funding in 2007, is organized around three projects and three cores:

Project 1 – Isolation Chemistry of Tropical Plants and Biological Evaluation

(Ohio State; Project Leader, Dr. A. Douglas Kinghorn)

Project 1 involves the isolation chemistry of bioactive tropical plants to be collected by Project 2, inclusive of extraction, dereplication, compound purification, structure elucidation and scale-up isolation stages. More recently, work has … Continue reading OSUCCC – James receives $7 million Program Project NCI grant renewal

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.